A reliable biomarker
Indication
Diagnosis and prognosis of prostate cancer
Development status
Development for commercial use is planned
Patents
U.S. Granted and World pending
Partner
Discussions ongoing
Diagnostic - PSP94 immunoassay
Ambrilia’s PSP94 immunoassay is a simple, potential diagnostic tool to determine the stage, grade and aggressiveness of prostate cancer.
A recent study, conducted by Dr. Robert K. Nam of the Sunnybrook and Women’s College Health Sciences Center, University of Toronto, with the Prostate Secretory Protein of 94 amino acids (PSP94) immunoassay for the diagnosis and prognosis of prostate cancer, showed that Ambrilia’s PSP94 was better at detecting aggressive prostate cancer than the commercially-available markers PSA (Prostate Specific Antigen) and FTPSA (Free to Total PSA ratio).
PSP along with PSA and Prostate Acid Phosphatase (PAP) are the three most abundant proteins in seminal fluid. Levels of PSA above 4 ng/ml of blood can signal prostate cancer, but not always. As prostate cancer advances, the serum PSP94 level is seen to initially increase but then drops in highly advanced cancer. Ambrilia’s immunoassay measures the amount of free PSP94, bound PSP94 and PSP94 binding protein present in the serum. Studies have also shown that levels of PSP94 are hormone-independent and not affected by androgen or anti-androgen therapy. PSP94 assessments are therefore likely also to have utility during periods of androgen ablation therapy.
Licensing opportunities
For more information, please contact:
Daniel Böck, Ph.D.
Vice-President, Business Development and Licensing
Tel.: 514 751-2003 ext. 236
E-mail: dbock@ambrilia.com